公开(公告)号：US11264688B2

公开(公告)日：2022-03-01

申请号：US16624067

申请日：2018-05-23

Applicant: THALES SOLUTIONS ASIA PTE LTD ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE GRENOBLES ALPES ,  L'INSTITUT POLYTECHNIQUE DE GRENOBLE ,  UNIVERSITÉ DE LILLE ,  UNIVERSITÉ DE LIMOGES ,  NANYANG TECHNOLOGICAL UNIVERSITY

Inventor： Philippe Coquet ,  Beng Kang Tay ,  Mathieu Cometto ,  Dominique Baillargeat ,  Stéphane Bila ,  Kamel Frigui ,  Philippe Ferrari ,  Emmanuel Pistono ,  Florence Podevin

IPC: H01P11/00 ,  H01P3/12

Abstract: An interposer (16) and a substrate (10) incorporating the interposer (16) are provided. The interposer (16) includes one or more layers (18) and a cavity (20) defined in the one or more layers (18), the cavity (20) being configured as a waveguide for propagation of electromagnetic waves.

公开(公告)号：US20220017611A1

公开(公告)日：2022-01-20

申请号：US17413215

申请日：2019-12-12

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE LILLE ,  CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  HYBRIGENICS SERVICES SAS

Inventor： Luc BUEE ,  Isabelle LANDRIEU ,  Jean-Christophe RAIN ,  Elian DUPRE ,  Alexis ARRIAL ,  Clément DANIS

IPC: C07K16/18 ,  G01N33/68 ,  A61P25/28

Abstract: The invention relates to generation, optimization and characterisation of VHH targeted against Tau MTBD (microtubule-binding domain) with high affinity, obtained by screening from a naïve synthetic library. The inventors optimized version of a lead VHH which is able to inhibit Tau aggregation in vitro and in HEK 293 aggregation-reporting cellular model, providing a new tool in Tau immunotherapies. Accordingly the invention relates to new VHH antibody that specifically binds with high affinity Tau species, especially the epitope region involved in Tau aggregation. Moreover, the inventors found that immunization with the optimized version of this lead VHH prevented the formation of neurofibrillary tangles induced by injection of extracellular h-AD in mouse model. Thus, these specific antibodies can be used for the therapy of tauopathy disorders such as Progressive supranuclear palsy (PSP).

公开(公告)号：US20210179669A1

公开(公告)日：2021-06-17

申请号：US17102505

申请日：2020-11-24

Applicant: INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Institut Pasteur de Lille ,  Centre National de la Recherche Scientifique (CNRS) ,  Université de Lille ,  Centre Hospitalier Regional Universitaire de Lille

Inventor： Laurence COCQUEREL-DEPROY ,  Claire MONTPELLIER ,  Jean DUBUISSON ,  Anne GOFFARD

IPC: C07K14/005 ,  C07K16/10 ,  C12N7/00 ,  G01N33/576

Abstract: Hepatitis F virus (HEV) is responsible for over 50% of acute viral hepatitis cases worldwide. The inventors have now identified the precise sequence of infectious particle-associated ORF2 capsid protein. Strikingly, their analyses revealed that in infected patients, HEV produces three forms of the ORF2 capsid protein: ORF2i, ORF2g and ORF2c. The ORF2i protein is associated with infectious particles whereas ORF2g and ORF2c proteins are massively produced glycoproteins that are not associated with infectious particles and arc the major antigens present in HEV-infected patient sera. Accordingly, the ORF2i and ORF2g proteins are thus the subject matter of the present invention as well as antibodies specific for the proteins and diagnostic assays (e.g. ELISA) for the diagnosis of Hepatitis E virus infection.

公开(公告)号：US20200325075A1

公开(公告)日：2020-10-15

申请号：US16956132

申请日：2018-12-21

Applicant: THALES ,  UNIVERSITÉ DE LILLE ,  NANYANG TECHNOLOGICAL UNIVERSITY ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Matthieu PAWLIK ,  Edwin Hang Tong TEO ,  Philippe COQUET

IPC: C04B35/583 ,  C04B41/45 ,  C04B41/82 ,  C04B41/85 ,  C04B38/00 ,  C04B41/53 ,  H01L23/427

Abstract: The invention relates to a composite material based on boron nitride (BN(C)) in the form of a continuous structure; and a phase change material (PCM) incorporated within said continuous BN(C) structure and is embedded within a polymer layer, a process for manufacturing same, and the components that comprise same.

公开(公告)号：US20200216530A1

公开(公告)日：2020-07-09

申请号：US16633900

申请日：2018-07-24

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  INSTITUT PASTEUR DE LILLE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITÉ DE LILLE

Inventor： Lionel POULIN ,  Corentin LASSEAUX ,  Mathias CHAMAILLARD

IPC: C07K16/24 ,  A61K38/21

Abstract: Monocytopoiesis is a hematological process that supplies the periphery with monocytes and subsequently with macrophages and monocyte-derived dendritic cells. Typically, monocytes circulate in the bloodstream for a very short time before undergoing apoptosis, however, stimulatory signals can trigger monocyte survival by inhibiting the apoptotic pathway, and thus contribute to the maintenance of the inflammatory response. Accordingly, there is a need for methods and pharmaceutical compositions for modulating monocytopoiesis. Now, the inventors show that type I interferons signaling promote the differentiation of monocyte-derived phagocytes at the level of their progenitors. Importantly, IFN-alpha and -beta were found to efficiently generate the development of monocyte-derived antigen-presenting cells while having no impact on the precursor activity of conventional dendritic cells. Accordingly, modulators of type I interferon (e.g. neutralizing antibodies or type I IFN polypeptides) would be suitable for modulating monocytopoiesis in subjects in need thereof.

公开(公告)号：US20240424086A1

公开(公告)日：2024-12-26

申请号：US18689994

申请日：2022-09-07

Applicant: UNIVERSITE DE TOURS ,  INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) ,  UNIVERSITÉ DE LILLE ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  CENTRE HOSPITALIER UNIVERSITAIRE DE LILLE

Inventor： Nicolas AUBREY ,  Fanny BOURSIN ,  Zineb LAKHRIF ,  Isabelle DIMIER-POISSON ,  Mathieu EPARDAUD ,  Rodolphe CARPENTIER ,  Antoine TOUZE ,  Marie-Noëlle MEVELEC

IPC: A61K39/215 ,  A61K39/00 ,  A61P37/04 ,  C07K14/005 ,  G01N33/569

Abstract: A fusion protein including fragments of the spike protein and of the nucleoprotein of a coronavirus. Also a vaccine, a composition, a pharmaceutical composition, or a diagnostic kit including the fusion protein, a method for diagnosing an infection by a coronavirus and to a method for preventing or treating a coronavirus infection based on the use of the fusion protein.

公开(公告)号：US20240146065A1

公开(公告)日：2024-05-02

申请号：US18269545

申请日：2021-12-23

Applicant: Centre national de la recherche scientifique ,  Université de Lille ,  ECOLE POLYTECHNIQUE ,  TotalEnergies OneTech

Inventor： Gonzague HENRI ,  Philippe CORDIER ,  Tanguy LEVENT ,  Philippe PREUX ,  Yves BONNASSIEUX

IPC: H02J3/32 ,  H02J3/38

CPC classification number: H02J3/32 ,  H02J3/381 ,  H02J3/388 ,  H02J2203/10 ,  H02J2203/20 ,  H02J2300/10 ,  H02J2300/20 ,  H02J2300/40

Abstract: A method for controlling an electric microgrid comprising an electrical energy consuming element, an electrical energy production element and an electrical energy storage element, the method comprising the steps of extracting parameter values from a source model, the extraction phase being implemented by computer, initializing parameters of a target model with parameter values extracted from the source model, so as to obtain an initialized target model, the initialization phase being implemented by computer, and optimizing, according to a target domain and a target set of tasks, of the parameters of the initialized target model, so as to obtain a target model trained for the control of a target microgrid, the optimization phase being implemented by computer.

公开(公告)号：US11919854B2

公开(公告)日：2024-03-05

申请号：US17042806

申请日：2019-03-29

Applicant: Centre national de la recherche scientifique ,  CHRU de Lille ,  Universite Côte D'Azur ,  Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Université de Lille ,  YNCREA Hauts de France

Inventor： Valérie Vouret ,  Laetitia Douguet ,  Alina Ghinet ,  Germain Homerin ,  Benoît Guy Marie Rigo ,  Davy Jérémy Baudelet ,  Xavier Dezitter ,  Régis Millet ,  Christophe Furman

IPC: C07D207/16 ,  A61K31/4015 ,  A61K31/4025 ,  A61K31/4439 ,  A61K39/395 ,  A61P1/00 ,  A61P35/00 ,  C07D401/12 ,  C07D409/12

CPC classification number: C07D207/16 ,  A61K31/4015 ,  A61K31/4025 ,  A61K31/4439 ,  A61K39/395 ,  A61P1/00 ,  A61P35/00 ,  C07D401/12 ,  C07D409/12

Abstract: The present invention relates to compounds of formula (I), their enantiomers and their pharmaceutically acceptable salts, and their use in therapy, particularly for the treatment of cancer or inflammatory diseases.

公开(公告)号：US20220339322A1

公开(公告)日：2022-10-27

申请号：US17760568

申请日：2020-10-01

Applicant: INSERM (Institut National de la Santé et de la Researche Médecale) ,  Université de Lille ,  Institut Pasteur de Lille ,  Centre Hospitalier Régional Universitaire de Lille

Inventor： Sophie SUSEN ,  Delphine CORSEAUX ,  Yoann SOTTEJEAU ,  Mickael ROSA ,  Jérôme SOQUET ,  Eric VAN BELL ,  Bart STAELS ,  Annabelle DUPONT

IPC: A61L27/54 ,  A61K31/192 ,  A61K31/203 ,  A61K31/196 ,  A61L27/18

Abstract: Aortic valve calcification is a condition in which calcium deposits form on the aortic valve in the heart. These deposits can cause narrowing at the opening of the aortic valve. This narrowing can become severe enough to reduce blood flow through the aortic valve—a condition called aortic valve stenosis. The inventors have shown that retinoic acid decreases calcification and osteoblast-like phenotype in valvular interstitial cells (VICs). More particularly, RARα activation reduces calcification and osteoblast-like phenotype in VIC. On the contrary, ALDH1A1 inhibition increases calcification and osteoblast-like phenotype in VIC. Thus the results prompt to consider that use or retinoic acid receptor (RAR) agonists would be suitable for the reversing, preventing or delaying calcification of the aortic valve.

公开(公告)号：US20220228094A1

公开(公告)日：2022-07-21

申请号：US17607693

申请日：2020-04-30

Applicant: UNIVERSITEIT GENT ,  CNRS ,  ISEN YNCRÉA HAUTS-DE-FRANCE ,  UNIVERSITÉ DE LILLE ,  UNIVERSITÉ POLYTECHNIQUE HAUTS-DE-FRANCE ,  CENTRALE LILLE INSTITUTE

Inventor： Kevin BRAECKMANS ,  Ranhua XIONG ,  Majid LAYACHI ,  Anthony TREIZEBRE ,  Francois ANQUEZ ,  Quentin THOMMEN ,  Emmanuel COURTADE

IPC: C12M3/06 ,  C12M1/00

Abstract: A method to provide a microfluidic flow comprising a central flow and at least one outer flow, such that the central flow includes a first material and the at least one outer flow comprises a second material. One of the first material and the second material has cells and the other of the first material and the second material has solid particles. The method involves injection of a first suspension including the first material through a central inlet with a flow rate Q2 and injection of a second suspension comprising the second material through a pair of side inlets with a flow rate Q2, whereby the ratio of the flow rate Q2 over the flow rate Q1 is at least 4. A device provides such microfluidic flow and a method is provided to alter biological cells.